Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Conditions: Metastatic Gastric Cancer
Metastatic Adenocarcinoma of the Gastroesophageal Junction

First Posted Date: 2014-02-19

Last Posted Date: 2025-01-09

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT02065765

Locations: 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands
🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ulsan-si, Korea, Republic of

A Study of LY2835219 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2835219

First Posted Date: 2014-02-11

Last Posted Date: 2019-01-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT02059148

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: LY2835219
Drug: Trastuzumab
Drug: LY3023414
Drug: Endocrine therapy
Drug: Letrozole
Drug: Exemestane
Drug: Anastrozole
Drug: Tamoxifen
Drug: Fulvestrant
Drug: Everolimus
Drug: Pertuzumab
Drug: Loperamide

First Posted Date: 2014-02-06

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 198

Registration Number: NCT02057133

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 10 locations

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Phase 3

Terminated

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Tabalumab Auto-Injector
Drug: Tabalumab Prefilled Syringe

First Posted Date: 2014-01-20

Last Posted Date: 2018-06-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 226

Registration Number: NCT02041091

Locations: 🇺🇸
The Feinstein Institute for Medical Research, Manhasset, New York, United States
🇺🇸
Medvin Clinical Research, Covina, California, United States
🇺🇸
Desert Medical Advances, Palm Desert, California, United States

and more 39 locations

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

Phase 1

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Exenatide ER
Drug: LY3053102
Drug: Placebo
Drug: Metformin

First Posted Date: 2013-12-25

Last Posted Date: 2019-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT02020616

Locations: 🇺🇸
Orange County Research Center, Orange, California, United States
🇺🇸
Compass Research, Orlando, Florida, United States
🇺🇸
Clinilabs, Inc (New York), New York, New York, United States

and more 2 locations

A Study of LY2969822 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2969822
Drug: Placebo

First Posted Date: 2013-12-23

Last Posted Date: 2019-02-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 99

Registration Number: NCT02018887

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study of LY2835219 in Japanese Participants With Advanced Cancer

Phase 1

Completed

Conditions: Lymphoma
Neoplasm Metastasis

Interventions: Drug: LY2835219

First Posted Date: 2013-12-18

Last Posted Date: 2020-08-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT02014129

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Neoplasms
Neoplasm Metastasis
Melanoma
Colorectal Neoplasms

Interventions: Drug: LY3009120 capsule

First Posted Date: 2013-12-18

Last Posted Date: 2019-12-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 51

Registration Number: NCT02014116

Locations: 🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Prostate Cancer
Pancreatic Carcinoma
Solid Tumors
Breast Cancer
Melanoma
Renal Cell Carcinoma
Non-small Cell Lung Carcinoma
Ovarian Cancer
Colorectal Carcinoma

Interventions: Drug: Gemcitabine/carboplatin
Drug: Pegilodecakin
Drug: nivolumab
Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Drug: gemcitabine/nab-paclitaxel
Drug: Capecitabine
Drug: Pazopanib
Drug: Paclitaxel
Drug: Pembrolizumab

First Posted Date: 2013-12-12

Last Posted Date: 2024-11-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 353

Registration Number: NCT02009449

Locations: 🇺🇸
UCLA Medical Hematology & Oncology, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States

and more 7 locations

A Study of Galunisertib in Participants With Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Placebo
Drug: Galunisertib

First Posted Date: 2013-12-11

Last Posted Date: 2019-09-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 43

Registration Number: NCT02008318

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Home Terms & Conditions Privacy Policy